Shots: • The NDA filling is based on results of P-III SAMURAI and SPARTAN study assessing Lasmiditan vs PBO in patients with migrane with or without aura in adults • The collective results of the study demonstrated safety and efficacy of Lasmiditan, meeting all 1EP & 2EP, showing greater percentage of patients free of their […]Read More
Tags : Acute Treatment of Migrane
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US